Regimens that included doxorubicin and cyclophosphamide plus taxane (TaxAC) worked better than 6 cycles of docetaxel and cyclophosphamide (TC6) in women with a certain type of breast cancer, according to an evaluation of 3 adjuvant trials involving more than 4,200 individuals.

Participants—all of whom had high-risk human EGFR 2-negative breast cancer—were randomly assigned to 6 cycles of TC6 (n=2,125) or to a standard TaxAC regimen (n=2,117). Before evaluating each trial individually, investigators analyzed TC versus the TaxAC regimens relative to invasive disease-free survival (IDFS). They excluded patients who received TC6 plus bevacizumab. Among the results:

• There were 334 IDFS events at a median follow-up of ~3 years.
• The 4-year IDFS rate was ~88% for TC6 and ~91% for TaxAC.
• Tests for treatment interaction by protocol, hormone receptor status, and nodal status were negative.